CER Daily Newsfeed

Value Viewpoint: September 5, 2025

(9/5, Kimberly Westrich, LinkedIn) comments “New NPC research published in Health Affairs Scholar finds that post-approval cancer trials fell after the Inflation Reduction Act (IRA) passage, with a disproportionate impact on small molecule drugs...The authors found that after the IRA’s passage: Overall, monthly post-approval oncology trials fell by 40.0%, with sharper declines for small molecule drugs (45.3%) than for biologics (32.5%). The disproportionate decline for small molecule drugs translated into an additional reduction of 4.5 trials/month, when compared to biologics. The disproportionate decline for small molecule drugs was robust to a sensitivity analysis that limited the pre-IRA period to the post-COVID-19 era.” Full

Cemiplimab Shows 5-Year Survival Benefit in Advanced NSCLC With High PD-L1 Expression

(9/8, Skylar Jeremias, The American Journal of Managed Care) reports “...Cemiplimab significantly improved overall survival and progression-free survival compared to chemotherapy in advanced NSCLC with high PD-L1 expression. The EMPOWER-Lung 1 trial showed a median OS of 26.1 months for cemiplimab versus 13.3 months for chemotherapy.” Full

Real-World Data Show 12-Month Drug Survival Rates Among Anti-TNF Biosimilars in Psoriasis, PsA

(9/8, Deana Ferreri, PhD, The American Journal of Managed Care) reports “...Anti-TNF-α biosimilars showed a 91% drug survival rate at 12 months, with no significant differences between infliximab, etanercept, and adalimumab. Long-term effectiveness and safety of anti-TNF-α biosimilars were emphasized, despite the availability of newer biologics.” Full

It's Time to Rewire Organizations to Meet RWE’s Strategic and Operational Demands: An Interview with Jeff Trotter

(9/8, The Evidence Base) reports “...[Jeff Trotter:] Ultimately, it will require (re-)education about the value of science and the importance of unbiased facts. For those of us working in RWE – acknowledging both its benefits and limitations – the responsibility is to be as transparent as possible about our methods, to remain humble in how we frame our findings, and, more than ever, to be open about our affiliations and potential biases. If we cast light on our own limitations first, it becomes much harder for outsiders to dismiss the credibility of our work. And above all, we must keep patients at the center – including speaking out against poorly researched products that put them at risk.” Full

A Patient-Centered Pathway For Biomedical Innovation And Access

(9/8, June Cha, Health Affairs Forefront) comments “...By bringing patients to the center of value assessment and policy decisions, we make health care smarter, more just, and more effective. Precision medicine may provide the tools to target diseases, but patient engagement ensures we aim at the outcomes that truly matter. Realizing this vision of patient-informed, precision health care will yield a system that delivers value as patients define it: health, dignity, and quality of life.” Full

Joint Clinical Assessment in Europe: Progress, Challenges, and What’s Next

(9/8, Joanne Walker, The Evidence Base) comments “...The first wave of JCAs will provide valuable insight into how the new system functions in practice and how Member States integrate joint reports into their national HTA processes. These early experiences will be closely watched as the framework broadens, covering orphan medicines from 2028 and all centrally authorized medicines by 2030.” Full